Evidence map›Paper›PMID 36449569›Full record

ArticleEndocrine-related cancer2023

SDHx mutation and pituitary adenoma: can in vivo 1H-MR spectroscopy unravel the link?

Francesca Branzoli, Betty Salgues, Małgorzata Marjańska, Marie Laloi-Michelin, Philippe Herman, Lauriane Le Collen, Brigitte Delemer, Julien Riancho, Emmanuelle Kuhn, Christel Jublanc and 6 more

Open access · greenAbstract read
In one paragraph

Article in Endocrine-related cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Francesca BranzoliParis Brain Institute - Institut du Cerveau (ICM), Center for Neuroimaging Research (CENIR), Paris, France.
Betty SalguesSorbonne University, nuclear medicine department, Pitié-Salpêtrière Hospital, Assistance -Publique Hôpitaux de Paris, Paris, France.ORCID 0000-0002-0889-0226
Małgorzata MarjańskaCenter for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA.ORCID 0000-0002-4727-2447
Marie Laloi-MichelinEndocrinology department, Lariboisière Hospital, Assistance -Publique Hôpitaux de Paris, Paris, France.
Philippe HermanENT unit, Lariboisière Hospital, Assistance -Publique Hôpitaux de Paris, Paris-Cité University, INSERM U1141, Paris, France.
Lauriane Le CollenInserm/CNRS UMR 1283/8199, Pasteur Institute of Lille, EGID, University of Lille, Lille, France.
Brigitte DelemerDepartment of Endocrinology Diabetology, University Hospital Center of Reims, Reims, France.
Julien RianchoAP-HP, Hôpital Européen Georges Pompidou, Hypertension Unit, and Reference centre for rare adrenal diseases, Paris, France.ORCID 0000-0002-3002-1780
Emmanuelle KuhnPituitary Unit, Pitié-Salpêtrière Hospital APHP, Sorbonne University, Paris, France.
Christel JublancPituitary Unit, Pitié-Salpêtrière Hospital APHP, Sorbonne University, Paris, France.
Nelly BurnichonDépartement de médecine génomique des tumeurs et des cancers, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Laurence AmarAP-HP, Hôpital Européen Georges Pompidou, Hypertension Unit, and Reference centre for rare adrenal diseases, Paris, France.
Judith FavierUniversité Paris Cité, Inserm, PARCC, Paris, France.ORCID 0000-0001-8190-5853
Anne-Paule Gimenez-RoqueploDépartement de médecine génomique des tumeurs et des cancers, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Alexandre BuffetDépartement de médecine génomique des tumeurs et des cancers, AP-HP, Hôpital Européen Georges Pompidou, Paris, France.
Charlotte Lussey-LepoutreSorbonne University, nuclear medicine department, Pitié-Salpêtrière Hospital, Assistance -Publique Hôpitaux de Paris, Paris, France.ORCID 0000-0003-2228-0106
Inserm · FRAssistance Publique – Hôpitaux de Paris · FRCentre National de la Recherche Scientifique · FRSorbonne Université · FRCentre Hospitalier Universitaire de Reims · FRUniversity of Minnesota · US

Funding

TRD4 - Ultrahigh Field Engineering and SafetyP41EB027061 · NIBIB · UNIVERSITY OF MINNESOTA · PI Gregory John Metzger, KAMIL UGURBIL · 2019 to 2026
$11.7M
Institutional Center Cores for Advanced NeuroimagingP30NS076408 · NINDS · UNIVERSITY OF MINNESOTA · PI UGURBIL, KAMIL · 2012 to 2020
$4.2M
NIBIB NIH HHS P41 EB027061NINDS NIH HHS P30 NS076408
6 · The paper itself

Abstract

Germline mutations in genes encoding succinate dehydrogenase (SDH) are frequently involved in pheochromocytoma/paraganglioma (PPGL) development and were implicated in patients with the '3PAs' syndrome (associating pituitary adenoma (PA) and PPGL) or isolated PA. However, the causality link between SDHx mutation and PA remains difficult to establish, and in vivo tools for detecting hallmarks of SDH deficiency are scarce. Proton magnetic resonance spectroscopy (1H-MRS) can detect succinate in vivo as a biomarker of SDHx mutations in PGL. The objective of this study was to demonstrate the causality link between PA and SDH deficiency in vivo using 1H-MRS as a novel noninvasive tool for succinate detection in PA. Three SDHx-mutated patients suffering from a PPGL and a macroprolactinoma and one patient with an apparently sporadic non-functioning pituitary macroadenoma underwent MRI examination at 3 T. An optimized 1H-MRS semi-LASER sequence (TR = 2500 ms, TE = 144 ms) was employed for the detection of succinate in vivo. Succinate and choline-containing compounds were identified in the MR spectra as single resonances at 2.44 and 3.2 ppm, respectively. Choline compounds were detected in all the tumors (three PGL and four PAs), while a succinate peak was only observed in the three macroprolactinomas and the three PGL of SDHx-mutated patients, demonstrating SDH deficiency in these tumors. In conclusion, the detection of succinate by 1H-MRS as a hallmark of SDH deficiency in vivo is feasible in PA, laying the groundwork for a better understanding of the biological link between SDHx mutations and the development of these tumors.

Indexed as

AdenomaAdrenal Gland NeoplasmsParagangliomaPheochromocytomaPituitary NeoplasmsProlactinomaElectron Transport Complex IIGerm-Line MutationHumansMagnetic Resonance SpectroscopyMetabolism, Inborn ErrorsMitochondrial DiseasesMutationSuccinate DehydrogenaseSuccinic AcidElectron Transport Complex IISuccinate DehydrogenaseSuccinic Acidmagnetic resonance spectroscopyparagangliomapituitary adenomasuccinatesuccinate dehydrogenase

Identifiers

PMID36449569
PMCPMC9885742
OpenAlexW4310467672

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.